ARTICLE | Distillery Therapeutics
Inhibiting CAPN9 to treat fibrosis
July 25, 2019 11:26 PM UTC
INDICATION: Pulmonary fibrosis; liver fibrosis; cardiac fibrosis...
BCIQ Company Profiles
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
INDICATION: Pulmonary fibrosis; liver fibrosis; cardiac fibrosis...
BCIQ Company Profiles
BCIQ Company Profiles